Efavirenz/lamivudine/tenofovir

Efavirenz/lamivudine/tenofovir (EFV/3TC/TDF), sold under the brand name Telura among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.[1] It combines efavirenz, lamivudine, and tenofovir disoproxil.[1] As of 2019, it is listed by the World Health Organization as an alternative first line option to dolutegravir/lamivudine/tenofovir.[2] It is taken by mouth.[1]

Efavirenz/lamivudine/tenofovir
Combination of
EfavirenzNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleoside reverse transcriptase inhibitor
Clinical data
Trade namesTelura, Symfi, Symfi Lo
Other namesEFV/3TC/TDF
AHFS/Drugs.comProfessional Drug Facts
MedlinePlusa618028
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
KEGG

Side effects can include joint pain, sleepiness, headaches, depression, trouble sleeping, and itchiness.[1] Severe side effects may include depression, psychosis, or osteonecrosis.[1] In those with a history of epilepsy, it may increase the frequency of seizures.[1] Greater care should also be taken in those with kidney problems.[1] It is unclear if use during pregnancy is safe.[1][3]

It is on the World Health Organization's List of Essential Medicines.[4] The combination received tentative approval in the United States in 2014,[5] and was granted approval in February 2018.[6][7] Its availability and importance is supported by Medecins Sans Frontieres.[1]

It was approved as a generic medication in the United States in 2020.[8][9]

References
  1. "Efavirenz + lamivudine + tenofovir disoproxil fumarate (Addition) -- Adults". World Health Organization (WHO).
  2. World Health Organization (July 2019). Policy brief: update of recommendations on first- and second-line antiretroviral regimens. World Health Organization. hdl:10665/325892. WHO/CDS/HIV/19.15. License: CC BY-NC-SA 3.0 IGO.
  3. "Telura" (PDF). Mylan.in. 2014. Retrieved 13 December 2017.
  4. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  5. "HIV/AIDS History of Approvals - HIV/AIDS Historical Time Line 2010 - 2015". U.S. Food and Drug Administration (FDA). Retrieved 13 December 2017.
  6. "Drug Approval Package: Symfi Lo (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 9 October 2018. Retrieved 15 August 2020.
  7. "Drug Approval Package: Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 24 November 2018. Retrieved 15 August 2020.
  8. "Office of Generic Drugs 2020 Annual Report". U.S. Food and Drug Administration (FDA). Retrieved 12 February 2021.
  9. "Drug Approval Package: Efavirenz, Lamivudine and Tenofovir disoproxil". U.S. Food and Drug Administration (FDA). 26 November 2018. Retrieved 15 August 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.